首站-论文投稿智能助手
典型文献
Discovery of the anti-influenza A virus activity of SB216763 and cyclosporine A by mining infected cells and compound cellular signatures
文献摘要:
In this study,SB216763 and cyclosporine A were identified as anti-influenza A virus(IAV)agents by tran-scriptome signature reversion(TSR)analysis through deep mining of the cellular transcriptome of hu-man airway and lung cell lines infected with 3 strains of IAV and the chemical perturbations library.A synergistic effect of SB216763 and cyclosporine A against influenza A was disclosed by quantification of the network-based relationship,which was validated in vitro.Along with burgeoning omics approaches,transcriptome-based drug development is flourishing,which provides a novel insight into antivirals dis-covery with comprehensive cellular transcriptional information of disease and chemical perturbations in multicomponent intervention.This strategy can be applied as a new approach in discovering multitar-get antiviral agents from approved drugs,clinical compounds,natural products or other known bioactive compounds.
文献关键词:
作者姓名:
Ke Tang;You Wu;Shubing Chen;Yijing Xin;Ying Guo
作者机构:
State Key Laboratory of Bioactive Substance and Function of Natural Medicines,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China;Department of Pharmacology,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China
引用格式:
[1]Ke Tang;You Wu;Shubing Chen;Yijing Xin;Ying Guo-.Discovery of the anti-influenza A virus activity of SB216763 and cyclosporine A by mining infected cells and compound cellular signatures)[J].中国化学快报(英文版),2022(05):2541-2544
A类:
multitar
B类:
Discovery,influenza,virus,activity,SB216763,cyclosporine,by,mining,infected,cells,cellular,signatures,In,this,study,were,identified,IAV,agents,reversion,TSR,analysis,through,deep,transcriptome,hu,man,airway,lung,lines,strains,chemical,perturbations,library,synergistic,effect,against,was,disclosed,quantification,network,relationship,which,validated,vitro,Along,burgeoning,omics,approaches,development,flourishing,provides,novel,insight,into,antivirals,comprehensive,transcriptional,information,disease,multicomponent,intervention,This,strategy,can,be,applied,new,discovering,get,from,approved,drugs,clinical,compounds,natural,products,other,known,bioactive
AB值:
0.604283
相似文献
A live attenuated virus-based intranasal COVID-19 vaccine provides rapid,prolonged,and broad protection against SARS-CoV-2
Junyu Chen;Pui Wang;Lunzhi Yuan;Liang Zhang;Limin Zhang;Hui Zhao;Congjie Chen;Xijing Wang;Jinle Han;Yaode Chen;Jizong Jia;Zhen Lu;Junping Hong;Zicen Lu;Qian Wang;Rirong Chen;Ruoyao Qi;Jian Ma;Min Zhou;Huan Yu;Chunlan Zhuang;Xiaohui Liu;Qiangyuan Han;Guosong Wang;Yingying Su;Quan Yuan;Tong Cheng;Ting Wu;Xiangzhong Ye;Tianying Zhang;Changgui Li;Jun Zhang;Huachen Zhu;Yixin Chen;Honglin Chen;Ningshao Xia-State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics,National Institute of Diagnostics and Vaccine Development in Infectious Diseases,School of Life Sciences,School of Public Health,Xiamen University,Xiamen 361102,China;State Key Laboratory of Emerging Infectious Diseases,School of Public Health,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Hong Kong 999077,China;National Institute for Food and Drug Control,Beijing 102629,China;Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd.,Beijing 102206,China;Guangdong-Hong Kong Joint Laboratory of Emerging Infectious Diseases/Joint Laboratory for International Collaboration in Virology and Emerging Infectious Diseases,Joint Institute of Virology(STU/HKU),Shantou University,Shantou 515063,China;EKIH Pathogen Research Institute,Shenzhen 518067,China
Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo
Fanxiang Yin;Ran Zhao;Dhilli Rao Gorja;Xiaorong Fu;Ning Lu;Hai Huang;Beibei Xu;Hanyong Chen;Jung-Hyun Shim;Kangdong Liu;Zhi Li;Kyle Vaughn Laster;Zigang Dong;Mee-Hyun Lee-Department of Pathophysiology,School of Basic Medical Sciences,Zhengzhou University,Zhengzhou 450001,China;China-US(Henan)Hormel Cancer Institute,Zhengzhou 450008,China;Translational Medical Center,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;The Hormel Institute,University of Minnesota,Austin,MN 55912,USA;Department of Biomedicine,Health&Life Convergencen Science,BK21 Four,College of Pharmacy,Mokpo National University,Jeonnam 58554,Republic of Korea;The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention,Zhengzhou 450001,China;Department of General Surgery,the Affiliated Tumor Hospital of Zhengzhou University,Zhengzhou 450008,China;College of Korean Medicine,Dongshin University,Naju 58245,Republic of Korea
Evolution of drug regulations and regulatory innovation for anticancer drugs in China
Yang Liu;Ning Zhang;Cuicui Xie;Yale Jiang;Yunhe Qin;Liyun Zhou;Yi Fan;Lianjie Ren;Chen Yin;Huan Yang;Wei Xie;Qing Zhai;Guanqiao Li;Hongzhuan Chen;Xiaoyuan Chen-Tsinghua Clinical Research Institute(TCRI),School of Medicine,Tsinghua University,Beijing 100084,China;Center for Drug Evaluation,National Medical Products Administration,Beijing 100038,China;Pharmcube(Beijing)Co.,Ltd.,Beijing 100102,China;Department of Clinical Pharmacy,Cancer Hospital of Fudan University,Shanghai 200032,China;Vanke School of Public Health,Tsinghua University,Beijing 100084,China;Shanghai Collaborative Innovation Center for Translational Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Office of Clinical Trial Institute,Beijing Tsinghua Changgung Hospital,Beijing 102218,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。